Literature DB >> 15625860

Synthesis of a nonreducible cyclic analog of somatostatin having only growth hormone release inhibiting activity.

V M Garsky1, D E Clark, N H Grant.   

Abstract

A nonreducible cyclic analog of somatostatin (SRIF) was prepared by a combination of solid phase and solution peptide synthesis. The compound, gamma-Abu-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Asp-OH, was tested for its effect on the release of growth hormone, glucagon and insulin in rats. It significantly suppressed pentobarbital-stimulated growth hormone release but showed no effect on arginine-stimulated glucagon or insulin release. The linear form, NH2-gamma-Abu-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Asp-OH, was also prepared and tested in vivo. It was shown to have only slight activity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 15625860     DOI: 10.1016/0006-291x(76)90208-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  [Phe4]somatostatin: a potent, selective inhibitor of growth hormone release.

Authors:  C A Meyers; D H Coy; W A Murphy; T W Redding; A Arimura; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.